Treating sexual desire disorders with flibanserin

• US 8,227,471 B2
• Filed: 09/21/2006
• Issued: 07/24/2012
• Est. Priority Date: 10/20/2001
• Status: Expired due to Term

• Current Assignee: Sprout Pharmaceuticals, Inc. (Sprout2, Inc.)
• Original Assignee: Sprout Pharmaceuticals, Inc. (Sprout2, Inc.)
• Inventors: Borsini, Franco, Evans, Kenneth Robert
• Primary Examiner(s): Blanchard, David J
• Assistant Examiner(s): Love, Trevor M
• Application Number:
  US11/524,268
• Publication Number:
  US 20070072872A1
• Time in Patent Office: 2,133 Days
• Field of Search: None
• US Class Current: 514/254.06
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.

Claims

1. A method of treating a patient having hypoactive sexual desire disorder, comprising administering a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to the patient to treat hypoactive sexual desire disorder.

2. The method of claim 1, wherein the patient is male.

3. The method of claim 1, wherein the amount administered is between 0.1 and 400 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

4. The method of claim 1, wherein the amount administered is between 1 and 300 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

5. The method of claim 1, wherein the amount administered is between 2 and 200 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

6. The method of claim 1, wherein the amount administered is in a dosage unit containing from 0.01 to 100 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

7. The method of claim 1, wherein the amount administered is in a dosage unit containing from 0.1 to 50 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

8. The method of claim 1 wherein the amount administered is in a dosage unit containing 150 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

9. The method of claim 1, wherein the amount administered is in a dosage unit containing 100 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

10. The method of claim 1, wherein the amount administered is in a dosage unit containing 80 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

11. The method of claim 1, wherein the amount administered is in a dosage unit containing 50 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

12. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof selected from the salts formed by the acids selected from the group consisting of succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid, citric acid, and mixtures thereof.

13. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with succinic acid.

14. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with hydrobromic acid.

15. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with acetic acid.

16. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with fumaric acid.

17. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with maleic acid.

18. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with methanesulphonic acid.

19. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with lactic acid.

20. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with phosphoric acid.

21. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with hydrochloric acid.

22. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with sulphuric acid.

23. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with tartaric acid.

24. A method according to claim 1, wherein flibanserin is administered in the form of a pharmaceutically acceptable acid addition salt thereof, wherein the salt is formed with citric acid.